cyclopropyl(2-methoxyphenyl)methanol | 400613-89-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: cyclopropyl(2-methoxyphenyl)methanol
• 英文别名: (Cyclopropyl) (2-methoxyphenyl)methanol；cyclopropyl-(2-methoxyphenyl)methanol
• CAS: 400613-89-0
• 化学式: C₁₁H₁₄O₂
• 分子量: 178.231
• InChiKey: OOINFLCGCGHFCK-UHFFFAOYSA-N

物化性质

• 沸点：
  305.5±25.0 °C(Predicted)
• 密度：
  1.158±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  29.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  cyclopropyl(2-methoxyphenyl)methanol 在 环丙基溴化镁 、 亚磷酸二乙酯 作用下， 以 四氢呋喃 为溶剂， 反应 5.0h， 以86.4 mg的产率得到(E)-1-(4-bromobut-1-enyl)-2-methoxybenzene
  参考文献：
  名称：

  均烯丙基溴的合成方法

  摘要：

  环丙基格氏试剂在亚磷酸二乙酯的存在下与羰基化合物反应生成均烯丙基溴化物。该反应在温和条件下以一锅法有效地进行，产率中等至良好。

  DOI：

  10.1021/jo400580n
• 作为产物：
  描述：

  2-溴苯甲醚 、 环丙甲醛 在 碘 、 magnesium 作用下， 以 乙醚 为溶剂， 反应 5.0h， 以53%的产率得到cyclopropyl(2-methoxyphenyl)methanol
  参考文献：
  名称：

  CuBr 2催化环丙基甲醇与DMF的开环/甲酰化反应合成甲酸酯

  摘要：

  通过使用N，N-二甲基甲酰胺（DMF）作为CHO和溶剂的来源，已经开发出前所未有的合成甲酸酯的方法。该反应经历环丙基甲醇的开环反应并原位形成均烯丙基醇，后者与DMF反应生成所需的产物。具有不同基团的底物环丙基甲醇顺利参与该过程，并以中等至良好的收率获得了所需的产物。

  DOI：

  10.1016/j.tetlet.2020.152506

文献信息

• Gold- and Silver-Catalyzed Tandem Amination/Ring Expansion of Cyclopropyl Methanols with Sulfonamides as an Expedient Route to Pyrrolidines
  作者：Weidong Rao、Philip Wai Hong Chan

  DOI：10.1002/chem.200801242

  日期：2008.11.17

  An efficient synthetic route to pyrrolidines that relies on AuCl/AgOTf-catalyzed tandem amination/ring expansion of substituted cyclopropyl methanols with sulfonamides is reported herein. The reactions proceed rapidly at 100 degrees C with catalyst loadings as low as 2 mol % and produce the pyrrolidine products in yields of 30-95 %. The method was shown to be applicable to a broad range of cyclopropyl

  本文报道了依赖于AuCl / AgOTf催化的串联磺胺化/取代的环丙基甲醇与磺酰胺的环吡咯烷酮的有效合成途径。反应在100℃下以低至2mol％的催化剂负载快速进行，并以30-95％的产率产生吡咯烷产物。已证明该方法适用于多种环丙基甲醇，包括未活化的环丙基甲醇和含有吸电子，给电子和空间需求取代基的磺酰胺底物。提示该机理涉及通过AuCl / AgOTf催化剂活化醇底物，然后使原料电离，这引起环丙烷部分的开环并被磺酰胺亲核试剂捕获。
• Calcium receptor antagonist
  申请人：——

  公开号：US20040006130A1

  公开（公告）日：2004-01-08

  A compound of the formula [I] 1 wherein R 1 is optionally substituted aryl group or optionally substituted heteroaryl group; R 2 is optionally substituted C 1-6 alkyl group, C 3-7 cycloalkyl group and the like; R 3 is hydrogen atom, C 1-6 alkyl group, hydroxyl group and the like; R 4 is hydrogen atom, C 1-6 alkyl group and the like; R 5 and R 6 are each C 1-6 alkyl group and the like; R 7 is optionally substituted aryl group or optionally substituted heteroaryl group; X 1 , X 2 and X 3 are each C 1-6 alkylene group and the like; and X 4 and X 5 are each a single bond, methylene group and the like, a salt thereof, a solvate thereof or a prodrug thereof, and a pharmaceutical composition containing the compound, particularly a calcium receptor antagonist and a therapeutic agent for osteoporosis, are provided. The compound of the present invention is useful as a therapeutic drug of diseases accompanied by abnormal calcium homeostasis, or osteoporosis, hypoparathyreosis, osteosarcoma, periodontal disease, bone fracture, steoarthrosis, chronic rheumatoid arthritis, Paget's disease, humoral hypercalcemia, autosomal dominant hypocalcemia and the like. In addition, an intermediate for the compound is provided.

  式为[I]的化合物，其中R1是可选择取代的芳基或可选择取代的杂环基；R2是可选择取代的C1-6烷基、C3-7环烷基等；R3是氢原子、C1-6烷基、羟基等；R4是氢原子、C1-6烷基等；R5和R6分别是C1-6烷基等；R7是可选择取代的芳基或可选择取代的杂环基；X1、X2和X3分别是C1-6亚烷基等；X4和X5分别是单键、亚甲基基团等，提供其盐、溶剂合物或前药，以及含有该化合物的药物组合物，特别是一种钙受体拮抗剂和治疗骨质疏松症的药物。本发明的化合物可用作伴有异常钙稳态或骨质疏松症、甲状旁腺功能减退症、骨肉瘤、牙周病、骨折、骨关节炎、慢性类风湿关节炎、帕盖特病、体液性高钙血症、常染色体显性低钙血症等疾病的治疗药物。此外，还提供了该化合物的中间体。
• Calcium receptor antagonists
  申请人：Shinagawa Yuko

  公开号：US20050107448A1

  公开（公告）日：2005-05-19

  A compound of the formula [I] wherein R 1 is optionally substituted aryl group or optionally substituted heteroaryl group; R 2 is optionally substituted C 1-6 alkyl group, C 3-7 cycloalkyl group and the like; R 3 is hydrogen atom, C 1-6 alkyl group, hydroxyl group and the like; R 4 is hydrogen atom, C 1-6 alkyl group and the like; R 5 and R 6 are each C 1-6 alkyl group and the like; R 7 is optionally substituted aryl group or optionally substituted heteroaryl group; X 1 , X 2 and X 3 are each C 1-6 alkylene group and the like; and X 4 and X 5 are each a single bond, methylene group and the like, a salt thereof, a solvate thereof or a prodrug thereof, and a pharmaceutical composition containing the compound, particularly a calcium receptor antagonist and a therapeutic agent for osteoporosis, are provided. The compound of the present invention is useful as a therapeutic drug of diseases accompanied by abnormal calcium homeostasis, or osteoporosis, hypoparathyreosis, osteosarcoma, periodontal disease, bone fracture, steoarthrosis, chronic rheumatoid arthritis, Paget's disease, humoral hypercalcemia, autosomal dominant hypocalcemia and the like. In addition, an intermediate for the compound is provided.

  本发明提供了式[I]的化合物，其中R1是可选取代芳基或可选取代杂环基；R2是可选取代C1-6烷基、C3-7环烷基等；R3是氢原子、C1-6烷基、羟基等；R4是氢原子、C1-6烷基等；R5和R6分别是C1-6烷基等；R7是可选取代芳基或可选取代杂环基；X1、X2和X3分别是C1-6亚烷基等；X4和X5分别是单键、亚甲基等。本发明还提供了该化合物的盐、溶剂化物或前药，以及包含该化合物的药物组合物，特别是钙受体拮抗剂和治疗骨质疏松症的药物。本发明的化合物可用作伴随异常钙稳态或骨质疏松症、低副甲状腺素血症、骨肉瘤、牙周病、骨折、骨关节炎、慢性类风湿性关节炎、帕盖特病、体液性高钙血症、常染色体显性低钙血症等疾病的治疗药物。此外，还提供了该化合物的中间体。
• Palladium-catalyzed stereoselective ring-opening reaction of aryl cyclopropyl ketones
  作者：Yan-Zuo Chen、Neng Wang、Zong-Rui Hou、Xian-Li Zhou、Xiaohuan Li、Feng Gao、Ting Jiang

  DOI：10.1039/d2ob00719c

  日期：——

  β-unsaturated ketones could be obtained by palladium-catalyzed ring-opening of mono-substituted cyclopropyl ketones efficiently and systematically. (E)-1-Arylbut-2-en-1-ones were generated from aryl cyclopropyl ketones stereoselectively in yields of 23–89% by the Pd(OAc)2/PCy3 catalytic system. The reaction exhibited stereoselectivity (only E products were found) and was suitable for both phenyl and

  在此，我们报道通过钯催化的单取代环丙基酮的开环可以有效且系统地获得α,β-不饱和酮。( E )-1-Arylbut-2-en-1-ones 通过 Pd(OAc) 2 /PCy 3催化体系由芳基环丙基酮立体选择性生成，收率为 23-89% 。该反应表现出立体选择性（仅发现E产物）并且适用于苯基和杂芳基环丙基酮。
• Rapid Access to Arylated and Allylated Cyclopropanes <i>via</i> Brønsted Acid-Catalyzed Dehydrative Coupling of Cyclopropylcarbinols
  作者：Naveen Yadav、Jabir Khan、Aparna Tyagi、Sanjay Singh、Chinmoy Kumar Hazra

  DOI：10.1021/acs.joc.2c00690

  日期：2022.5.20

  A regioselective protocol for the synthesis of cyclopropyl derivatives that relies on Brookhart acid-catalyzed dehydrative coupling over substituted cyclopropylcarbinols without rearrangement is reported herein. The reactions proceed promptly at 25 °C with only 2.0 mol % catalyst loading and produce the cyclopropyl derivatives in excellent yields. This method is well tolerated with a vast range of

  本文报道了一种用于合成环丙基衍生物的区域选择性方案，该方案依赖于 Brookhart 酸催化的在取代的环丙基甲醇上的脱水偶联而不发生重排。反应在 25 °C 下迅速进行，催化剂负载量仅为 2.0 mol%，并以优异的收率产生环丙基衍生物。这种方法对包括脂肪族环丙醇在内的多种环丙醇具有良好的耐受性，其中没有获得消除产物，证明了该协议的实用性。此外，Hammett 相关性表明形成环丙基羰基阳离子，然后发生偶联反应。一个非常有效的克级反应也已被证明具有高周转数。